# US 2004/0082013 A1 · Methods for screening for substances which inhibit fp prostanoid receptor interaction with a compound having pgf2alpha activity and methods of treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082013 A1
- Document ID: US20040082013A1
- Status: Published application
- Kind: A1
- Application number: 10/466,545
- Filed: 2003-12-23
- Published: 2004-04-29
- Earliest claimed: 2003-12-23
- Inventors: John W Regan
- Web page: https://patentgrep.com/patent/US20040082013A1

## CPC

- G01N 33/88: involving prostaglandins {or their receptors}
- C12Q 2600/158: Expression markers
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2500/10: involving cells
- G01N 2510/00: Detection of programmed cell death, i.e. apoptosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides mehtods for screening for substances which inhibit the interaction between a FP prostanoid receptor and a compoudn having PGF2αalphaactivity, methods for inhibiting the interaction, methods of inhibiting signaling mediated by βbeta-catenin, and methods of treating cancer.

## Claims

### Claim 1

A method of screening for substances which inhibit the interaction between a FP prostanoid receptors and a compound having PGF2α activity comprising
contacting a cell expressing the FP prostanoid receptors with the substance to be screened;
contacting said cell with said PGF2α compound; and
assaying the presence or absence of interaction between FP prostanoid receptors and PGF2α compound, wherein the absence of an interaction between FP prostanoid receptors and PGF2α compound indicates the substance inhibits the interaction.

### Claim 2 (depends on 1)

The method of claim 1, wherein said assaying comprises analyzing the morphology of the cell; wherein said morphology is selected from the group consisting of cell rounding, loss of filopodia, and formation of cell aggregates; wherein an absence of a change in cell morphology compared to a cell not contacted with PGF2α compound indicates inhibition of the interaction.

### Claim 3 (depends on 1)

The method of claim 1, wherein the assaying comprises measuring apoptosis in said cell.

### Claim 4 (depends on 1)

The method of claim 1, wherein said cell endogenously expresses the FP prostanoid receptor.

### Claim 5 (depends on 1)

The method of claim 1, wherein said assaying comprises measuring the transcription activity of a Tcf/Lef responsive promoter.

### Claim 6 (depends on 5)

The method of claim 5, wherein said assaying comprises a detection method selected from the group consisting of RT-PCR, Northern blot, luciferase reporter gene, β-gal reporter gene, and other reporters.

### Claim 7 (depends on 1)

The method of claim 1, wherein said assaying comprises measuring the level of phosphorylation of β-catenin in the cell, wherein an increased level of phosphorylation compared to the β-catenin in a cell not contacted with said substance indicates the inhibition of the interaction.

### Claim 8 (depends on 1)

The method of claim 1, wherein said substance is an antibody.

### Claim 9 (depends on 8)

The method of claim 8, wherein said antibody binds to the FP prostanoid receptor.

### Claim 10 (depends on 8)

The method of claim 8, wherein said antibody binds to PGF2α compound.

### Claim 11 (depends on 1)

The method of claim 1, wherein said PGF2α compound is PGF2α.

### Claim 12 (depends on 1)

The method of claim 1, wherein said assaying comprises measuring changes in at least one member selected from the group consisting of inositol phosphate stimulation, activation of Rho, stress fiber formation and phosphorylation of P125.

### Claim 13 (depends on 1)

The method of claim 1, wherein said FP prostanoid receptor is FPB.

### Claim 14

A method of screening for substances which inhibit the interaction between a FP prostanoid receptor and a compound having PGF2α activity comprising
introducing and expressing a polynucleotide which encodes the FP prostanoid receptor;
contacting said cell expressing the FP prostanoid receptor with the substance to be screened;
contacting said cell with said PGF2α compound; and
assaying the presence or absence of interaction between FP prostanoid receptor and PGF2α compound, wherein the absence of an interaction between FP prostanoid receptor and PGF2α indicates the substance inhibits the interaction.

### Claim 15

A method of inhibiting the interaction between FP prostanoid receptor and a compound having PGF2α activity comprising contacting said FPA with a substance which is capable of inhibiting said interaction.

### Claim 16

A method of inhibiting β-catenin signaling comprising contacting a cell expressing FP prostanoid receptor with a substance which is capable of inhibiting the interaction between FP prostanoid receptor and a compound having PGF2α activity.

### Claim 17

A method of inhibiting G12 and G13 mediated signaling comprising contacting a cell expressing FP prostanoid receptor with a substance which is capable of inhibiting the interaction between FP prostanoid receptor and a compound having PGF2α activity.

### Claim 18

A method of treating cancer comprising administering to a patient in need thereof a substance which inhibits the interaction between FP prostanoid receptor and a compound having PGF2α activity in an amount sufficient to inhibit said interaction.

### Claim 19 (depends on 18)

The method of claim 18, wherein said cancer is colorectal cancer.

### Claim 20

A method of screening for substances which inhibit β-catenin signaling comprising
contacting a cell expressing FP prostanoid receptor with the substance to be screened;
contacting said cell with a compound having PGF2α activity; and
assaying the signaling activity, phosphorylation and/or the subcellular localization of the β-catenin; wherein a change in one or more of the signaling activity, phosphorylation and/or the subcellular localization is lower than the signaling activity, phosphorylation and/or the subcellular localization compared to a cell not contacted with the substance indicates the substance inhibits the interaction β-catenin signaling.

### Claim 21

A method of screening for a substance for their ability to inhibit cancer cell growth comprising
contacting a cell expressing FP prostanoid receptor with the substance to be screened;
contacting said cell with a compound having PGF2α activity; and
assaying the change in cell growth, wherein a decrease in cell growth is indicates an inhibition of cancer cell growth.

### Claim 22 (depends on 21)

The method of claim 21, wherein said assaying comprises analyzing the morphology of the cell; wherein said morphology is selected from the group consisting of cell rounding, loss of filopodia, and formation of cell aggregates; wherein an absence of a change in cell morphology compared to a cell not contacted with said PGF2α compound indicates inhibition of the interaction.

### Claim 22 (depends on 21)

The method of claim 21, wherein the assaying comprises measuring apoptosis in said cell.

### Claim 23 (depends on 21)

The method of claim 21, wherein said cell endogenously expresses the FP prostanoid receptor.

### Claim 24 (depends on 21)

The method of claim 21, wherein said assaying comprises measuring the transcription activity of a Tcf/Lef responsive promoter.

### Claim 25 (depends on 24)

The method of claim 24, wherein said assaying comprises a detection method selected from the group consisting of RT-PCR, Northern blot, luciferase reporter gene, β-gal reporter gene, and other reporters.

### Claim 26 (depends on 21)

The method of claim 21, wherein said assaying comprises measuring the level of phosphorylation of β-catenin in the cell, wherein an increased level of phosphorylation compared to the β-catenin in a cell not contacted with said substance indicates the inhibition of the interaction.

### Claim 27 (depends on 21)

The method of claim 21, wherein said substance is an antibody.

### Claim 28 (depends on 27)

The method of claim 27, wherein said antibody binds to the FP prostanoid receptor.

### Claim 29 (depends on 27)

The method of claim 27, wherein said antibody binds to PGF2α compound.

### Claim 30 (depends on 21)

The method of claim 21, wherein said PGF2α compound is PGF2α.

### Claim 31 (depends on 21)

The method of claim 21, wherein said assaying comprises measuring changes in at least one member selected from the group consisting of inositol phosphate stimulation, activation of Rho, stress fiber formation and phosphorylation of P125.

### Claim 32 (depends on 21)

The method of claim 21, wherein said FP prostanoid receptor is FPB.

### Claim 33 (depends on 21)

The method of claim 21, wherein said inhibiting cancer cell growth comprises treating cancer.

### Claim 34 (depends on 21)

The method of claim 21, wherein said method is performed in vitro or in vivo.
